Products / Services

To meet physicians and patients’ needs, we are one of the few companies to successfully build a comprehensive and multi-dimensional product and service portfolio targeting over 20 cancer types covering the entire cycle of cancer early detection and screening, diagnosis, treatment selection and monitoring.    

Genecast MRD MinerVa Prime

Molecular residual disease (MRD) refers to the presence of a small number of cancer cells or molecules related to cancer that remain in the body after treatment, which can not be detected with current standard medical care.


14.1-MinerVa Prime 插图1.png

Genecast MRD MinerVa Prime based on the detection of minute amounts of circulating cell-free tumour DNA (ctDNA) enable MRD detection in patients with various malignancies.


14.2-MinerVa Prime 插图2.png


Landmark MRD is the most important prognostic biomarker during post-surgical follow-up assessments*


MinerVa Prime 插图3.png


Longtitudinal MRD monitors cancer recurrence with a lead time of 5.6 months*


14.4-MinerVa Prime 插图4.png


*Fei Zhou | MRD predicts clinical outcomes of patients with early-stage EGFR-mutant NSCLC: a post-hoc biomarker analysis of EVIDENCE 2024 World Conference on Lung Cancer.


14.5-MinerVa Prime 插图5.png